NCT05141682View on ClinicalTrials.gov

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

January 15, 2026

Study Completion Date

January 31, 2026

Conditions

T-Cell Large Granular Lymphocyte Leukemia

Interventions

DRUG

Oral Azacitidine

Given PO

Trial Locations (2)

22908

RECRUITING

University of Virginia, Charlottesville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Jonathan Brammer

OTHER

NCT05141682 - Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter